We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408
Read MoreHide Full Article
Krystal Biotech, Inc. (KRYS - Free Report) announced initial clinical data updates on its two inhaled genetic medicine pipeline candidates, KB407 and KB408, which are being developed in early-stage studies for treating rare respiratory diseases.
Shares of the company were down 7.3% on Dec. 12 following the announcement of the news.
KB407 is being developed in a phase I study for the treatment of cystic fibrosis (CF), while KB408 is being developed in a phase I study for treating alpha-1 antitrypsin deficiency (AATD).
The latest clinical updates include molecular data as well as safety and tolerability data for both KB407 and KB408.
Year to date, shares of Krystal Biotech have rallied 39.8% against the industry’s decline of 8.7%.
Image Source: Zacks Investment Research
More on KRYS' Development of KB407
The open-label, phase I CORAL-1 study is evaluating KB407 for treating adult patients with CF. The company recently activated two additional clinical sites for its KB407 phase I CORAL-1 study.
Per the company, the CORAL-1 study is designed to include up to three dose escalation cohorts evaluating either one, two, or four daily administrations of 109 PFU of KB407 via inhalation.
Based on the preclinical data submitted to date by Krystal Biotech, the Cystic Fibrosis Foundation (CFF) Therapeutic Development Network (TDN) Clinical Research Executive Committee has granted conditional sanctioning of the KB407 phase I CORAL-1 study protocol. It is subject to review by the data monitoring committee charter, if required, to match CFF TDN standards.
As of the data cut-off date of Dec 6, 2024, a total of five patients from Cohort 1 and Cohort 2 have been enrolled in the CORAL-1 study. Treatment with KB407 was well tolerated in all patients and no serious adverse events were observed.
KRYS plans to report data from Cohort 3 of the CORAL-1 study in the first half of 2025.
More on KRYS' Development of KB408
The open-label, phase I SERPENTINE-1 study is investigating KB408 for treating adult patients with AATD. In September, Krystal Biotech amended the protocol for its phase I SERPENTINE-1 study on KB408 to include mandatory bronchoscopies in this cohort to measure alpha-1 antitrypsin expression.
Per the company, the SERPENTINE-1 study is designed to include up to three dose escalation cohorts evaluating single administrations of 109, 1010 and 1011 PFU of KB408 via inhalation.
As of the data cut-off date of Dec 6, 2024, a total of seven patients from Cohort 1 and Cohort 2 have been enrolled in the SERPENTINE-1 study.
Clear evidence of SERPINA1 gene delivery and AAT expression following treatment with KB408 was observed in AATD patients and no serious adverse events were reported.
Additional updates on the SERPENTINE-1 study are expected in 2025.
In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Loss per share estimates for 2025 have narrowed from 56 cents to 35 cents during the same time. Year to date, shares of CTMX have declined 27.7%.
CTMX’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 115.70%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Loss per share estimates for 2025 have narrowed from $1.54 to 79 cents during the same time. Year to date, shares of SPRO have declined 25.2%.
SPRO’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 94.42%.
In the past 60 days, estimates for Castle Biosciences’ 2024 bottom line have moved from a loss of 58 cents per share to earnings of 34 cents per share. Loss per share estimates for 2025 have narrowed from $2.13 to $1.84 during the same time. Year to date, shares of CSTL have surged 34.9%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408
Krystal Biotech, Inc. (KRYS - Free Report) announced initial clinical data updates on its two inhaled genetic medicine pipeline candidates, KB407 and KB408, which are being developed in early-stage studies for treating rare respiratory diseases.
Shares of the company were down 7.3% on Dec. 12 following the announcement of the news.
KB407 is being developed in a phase I study for the treatment of cystic fibrosis (CF), while KB408 is being developed in a phase I study for treating alpha-1 antitrypsin deficiency (AATD).
The latest clinical updates include molecular data as well as safety and tolerability data for both KB407 and KB408.
Year to date, shares of Krystal Biotech have rallied 39.8% against the industry’s decline of 8.7%.
Image Source: Zacks Investment Research
More on KRYS' Development of KB407
The open-label, phase I CORAL-1 study is evaluating KB407 for treating adult patients with CF. The company recently activated two additional clinical sites for its KB407 phase I CORAL-1 study.
Per the company, the CORAL-1 study is designed to include up to three dose escalation cohorts evaluating either one, two, or four daily administrations of 109 PFU of KB407 via inhalation.
Based on the preclinical data submitted to date by Krystal Biotech, the Cystic Fibrosis Foundation (CFF) Therapeutic Development Network (TDN) Clinical Research Executive Committee has granted conditional sanctioning of the KB407 phase I CORAL-1 study protocol. It is subject to review by the data monitoring committee charter, if required, to match CFF TDN standards.
As of the data cut-off date of Dec 6, 2024, a total of five patients from Cohort 1 and Cohort 2 have been enrolled in the CORAL-1 study. Treatment with KB407 was well tolerated in all patients and no serious adverse events were observed.
KRYS plans to report data from Cohort 3 of the CORAL-1 study in the first half of 2025.
More on KRYS' Development of KB408
The open-label, phase I SERPENTINE-1 study is investigating KB408 for treating adult patients with AATD. In September, Krystal Biotech amended the protocol for its phase I SERPENTINE-1 study on KB408 to include mandatory bronchoscopies in this cohort to measure alpha-1 antitrypsin expression.
Per the company, the SERPENTINE-1 study is designed to include up to three dose escalation cohorts evaluating single administrations of 109, 1010 and 1011 PFU of KB408 via inhalation.
As of the data cut-off date of Dec 6, 2024, a total of seven patients from Cohort 1 and Cohort 2 have been enrolled in the SERPENTINE-1 study.
Clear evidence of SERPINA1 gene delivery and AAT expression following treatment with KB408 was observed in AATD patients and no serious adverse events were reported.
Additional updates on the SERPENTINE-1 study are expected in 2025.
Krystal Biotech, Inc. Price
Krystal Biotech, Inc. price | Krystal Biotech, Inc. Quote
KRYS' Zacks Rank & Key Picks
Krystal Biotech currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the biotech sector are CytomX Therapeutics, Inc. (CTMX - Free Report) , Spero Therapeutics, Inc. (SPRO - Free Report) and Castle Biosciences, Inc. (CSTL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Loss per share estimates for 2025 have narrowed from 56 cents to 35 cents during the same time. Year to date, shares of CTMX have declined 27.7%.
CTMX’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 115.70%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Loss per share estimates for 2025 have narrowed from $1.54 to 79 cents during the same time. Year to date, shares of SPRO have declined 25.2%.
SPRO’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 94.42%.
In the past 60 days, estimates for Castle Biosciences’ 2024 bottom line have moved from a loss of 58 cents per share to earnings of 34 cents per share. Loss per share estimates for 2025 have narrowed from $2.13 to $1.84 during the same time. Year to date, shares of CSTL have surged 34.9%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.